FTD-TPI + bevacizumab-UMC Utrecht

FTD-TPI + bevacizumab-UMC Utrecht refers to a combination therapy regimen being evaluated in the Phase II STARLIGHT trial at University Medical Center Utrecht. This therapeutic approach combines systemic treatment with trifluridine/tipiracil (FTD-TPI, an oral nucleoside-based chemotherapy) and bevacizumab (a monoclonal antibody targeting VEGF) alongside localized, individualized radioembolization using holmium-166 (166Ho) microspheres. The regimen is specifically investigated for patients with refractory, liver-dominant metastatic colorectal cancer (mCRC). FTD-TPI serves as both a cytotoxic agent and a potential radiosensitizer, while bevacizumab inhibits tumor angiogenesis and 166Ho-microspheres deliver targeted internal beta-radiation to hepatic lesions. The goal of this multi-modal strategy is to improve disease control in both intrahepatic and extrahepatic sites for patients who have failed standard therapies including fluoropyrimidines, oxaliplatin, and irinotecan.

Brand names

LonsurfAvastinQuiremSpheres

Other names

trifluridine/tipiracil + bevacizumab + 166Ho-microspheresTAS-102 + bevacizumab + holmium-166 radioembolization